First Migraine Prevention Drug Targeting Histamine Receptors, using a Transdermal Delivery System:  Technomark LS is the Series A Lead Investor

Technomark LS to lead $22M raise with a $7M commitment at $68.2M pre-money valuation; AgoneX is seeking the remaining $15M at the same valuation

Since 1987, Technomark has had an impeccable reputation in the life science industry for strategic planning, venture capital, and product development

AGX-201 prevents migraine initiation by stabilizing cell membranes and preventing histamine rush

Histamine receptor modulation permits more effective migraine prevention not seen in any other class of migraine preventive products, and this makes long-term adverse consequences extremely unlikely 

Data licenses and an industry-leading team facilitated FDA pre-IND consultation and leapfrog of pre-clinical phase 1 and 2a clinical trials, saving millions of dollars and years in development time

The migraine drug market is expected to quadruple to $12 billion by 2030, and currently available treatments only work in approximately 50% of patients, providing only partial relief 

$3 Billion Market, Expected to Quadruple to $12 billion by 2030

A significant portion of this large market is not adequately addressed by current drug therapies

Migraine affects 1 billion people across the world; it is the 3rd most prevalent illness and the 6th most disabling illness in the world; 39 million Americans suffer from migraines and 75% are women

US businesses lose an estimated $50 billion each year due to medical expenses and lost productivity caused by migraine

Sales of migraine products are expected to rise from the 10th highest to the 3rd highest in the CNS category from 2016 to 2026

There are two kinds of migraine treatments:

Preventative agents which aim to decrease frequency, severity and duration

Acute agents attempt to stop an ongoing migraine when it occurs

AgoneX’s AGX-201 is preventative, and the company believes it has the potential to be a better preventative than any other agents on the market

AGX-201 is the first drug in development which modulates histamine receptors – the root cause associated with the onset of migraine. AGX-201’s mechanism of delivery and action make it more convenient and better tolerated than other preventive migraine products

Better Efficacy AGX-201’s unique mechanism of action (MoA) modulates histamine receptors, stabilizing mast cell membranes, thereby decreasing mast cell degranulation and preventing migraine initiation

Reduction of Associated Symptoms As a result of its MoA, AGX-201 will prevent migraines, including associated symptoms such as brain fog, nausea, light and sound sensitivity and dizziness

Better Safety Unlike currently available treatments, AGX-201’s unique MoA does not alter normal physiological function; the majority of newer migraine preventives work by blocking CGRP or its receptor.  CGRP is a potent vasodilator that plays a protective role in recovery from certain life-threatening cardiovascular and cerebrovascular events.  These agents have not been on the market long enough to adequately assess this risk

Easy Delivery AGX-201’s molecular technology is delivered via a proprietary transdermal delivery system, and as a result, it is a very convenient dosage form and will be better tolerated than subcutaneous injections or oral formulations of current treatments

Potentially Lower Price Point Management anticipates AGX-201’s price will be well below recent entries into the market.  $5,000 per patient per year cost assumption has been used for AGX-201 forecasting

As an example, Nurtec costs up to $22K per year ($103 /pill x up to 18 doses per month x 12 months)

Potentially Faster Adoption The lower price point in addition to the ease of use, safety and efficacy features may allow for rapid adoption of the AGX platform by patients and providers, potentially leading to a larger overall market share

• Clinical Trial fails to demonstrate efficacy
• Unforeseen events or safety concerns halt further development or damage company’s reputation
• Shifting regulatory landscapes or new guidelines complicate approval pathways
• FDA requires Phase 3 Clinical Trial for approval, requiring additional capital
• Not meeting critical mass to eventually attract a strategic buyer
• A global pandemic which will divert attention to other medical therapies
• New medical technology can be slow to adopt during the first 1-2 years; Medical facilities are reluctant to quickly switch to new technology until proven over a period of time
• Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment